A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

COYA-301 is under clinical development by Coya Therapeutics and currently in Phase II for Alzheimer's Disease.

CSTI-500 is under clinical development by ConSynance Therapeutics and currently in Phase I for Prader-Willi Syndrome (PWS).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...